Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), today announced the pricing of the underwritten offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. Cyclacel has …
StreetInsider · 5/16/2013
Well, as we know there are two types of person in the stock market one is trader and another ... We told our members in facebook private group to buy Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC) this morning at $1.44. Now look at the price of the stock ...
Market News Call · 2/27/2015
The fund now owns 5.1% of the company’s outstanding stock, down from 5.9%. Likewise, the company entirely liquidated its position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC). Previously, Tang’s fund owned 765,198 shares of the stock.
INSIDER MONKEY · 1/17/2014
More from Bing News
CYCC has long been a thorn to many bio-tech investors. The company has struggled to garner significant interest since it's reverse merger with Xcyte Therapies in late 2005 and subsequent Nasdaq listing. As evident below, the stock has performed poorly ...
Seeking Alpha · 3/27/2014
Cyclacel Pharmaceuticals, Inc. (CYCC) announced this morning that a recent study at the University of Texas has shown that its seliciclib drug may potentially treat breast cancer cells that are resistant to hormone therapy. The drug is currently in Phase 2 ...
Investor Place · 2/17/2010
Here's a close-up examination of - and forecast for - Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Sequenom, Inc. (NASDAQ ... The chart of BIDU below says it all. This small cap stock went from rallying nicely in the latter part of last year o racing ...
Smallcap Network · ByJames E. Brumley · 4/19/2010
Cyclacel Pharmaceuticals, Inc. (CYCC) is one of Tuesday’s notable stocks in decline ... Over the past 5 trading sessions the stock has lost 3.74%. Shares of Cyclacel Pharmaceuticals, Inc. are down 29.60% year-over-year and 29.60% year-to-date.
Wall Street Pit · 12/16/2014
Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... Click Here Now Cyclacel (NASDAQ: CYCC ) is getting in gear to expand its capital base. The company is floating a new issue of common stock in an underwritten public offering.
The Motley Fool · ByEric Volkman · 5/16/2013
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing penny stocks, up 18.1% to $0.85 on 5.7x average daily volume. Cyclacel Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 209,000 shares per day.
Financial News Network Online · ByAdrienne Chilton · 2/26/2015
We would like to see more results on the CYC202 candidate before recommending the stock. As such, we maintain our Hold rating with a target price of $6.00." [url=]Read the full analyst …
ZACKS · 10/23/2007